The historical rank and industry rank for Mineralys Therapeutics's Equity-to-Asset or its related term are showing as below:
MLYS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.42 Med: -1.26 Max: 0.96
Current: 0.96
During the past 4 years, the highest Equity to Asset Ratio of Mineralys Therapeutics was 0.96. The lowest was -2.42. And the median was -1.26.
MLYS's Equity-to-Asset is ranked better than 96.43% of 1567
companies
in the Biotechnology industry
Industry Median: 0.66
vs MLYS: 0.96
Mineralys Therapeutics Equity-to-Asset Historical Data
The historical data trend for Mineralys Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mineralys Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Mineralys Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Mineralys Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Mineralys Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Mineralys Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Mineralys Therapeutics (Mineralys Therapeutics) Business Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MLYS has been successfully added to your 